PRESS RELEASE published on 03/27/2024 at 13:00, 5 months 23 days ago FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics FSD Pharma Inc. Multiple Sclerosis Lucid-21-302 INGENu CRO Pty Ltd. Phase 1 Clinical Study
BRIEF published on 03/11/2024 at 13:05, 6 months 8 days ago FSD Pharma annonce la soumission d'une demande d'essai clinique pour la boisson unbuzzd(TM) FSD Pharma Essai Clinique Métabolisme De L'alcool Produits Biopharmaceutiques Unbuzzd(TM)
BRIEF published on 03/11/2024 at 13:05, 6 months 8 days ago FSD Pharma Announces Submission of Clinical Trial Application for unbuzzd(TM) Beverage FSD Pharma Biopharmaceuticals Clinical Trial Alcohol Metabolism Unbuzzd(TM)
PRESS RELEASE published on 03/11/2024 at 13:00, 6 months 8 days ago FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM) FSD Pharma Inc. submits a Clinical Trial Application for a Phase-1b trial on unbuzzd™, a dietary supplement to assess safety and efficacy in alcohol metabolism. Expert team readies for trial recruitment FSD Pharma Inc. Unbuzzd™ Alcohol Metabolism Clinical Trial Application Phase-1b Trial
BRIEF published on 03/05/2024 at 14:05, 6 months 14 days ago FSD Pharma annonce les résultats positifs de l'étude de phase 1 pour le Lucid-21-302 lors du forum ACTRIMS 2024 FSD Pharma Sclérose En Plaques ACTRIMS 2024 Lucide-21-302 Étude De Phase 1
BRIEF published on 03/05/2024 at 14:05, 6 months 14 days ago FSD Pharma Announces Positive Phase-1 Study Results for Lucid-21-302 at ACTRIMS 2024 Forum FSD Pharma Multiple Sclerosis Lucid-21-302 Phase-1 Study ACTRIMS 2024
PRESS RELEASE published on 03/05/2024 at 14:00, 6 months 14 days ago FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects FSD Pharma Multiple Sclerosis ACTRIMS 2024 Forum Phase-1 Clinical Study Neuroprotective Compound
BRIEF published on 02/28/2024 at 14:00, 6 months 20 days ago FSD Pharma Règle des Dettes par Émission d'Actions et Accorde des RSUs Biopharmaceutique FSD Pharma Émission D'actions Traitement Neurodégénératif RSUs
BRIEF published on 02/28/2024 at 14:00, 6 months 20 days ago FSD Pharma Settles Debts through Issuance of Shares and Grants RSUs FSD Pharma Biopharmaceutical RSUs Issue Of Shares Neurodegenerative Treatment
PRESS RELEASE published on 02/28/2024 at 14:00, 6 months 20 days ago FSD Pharma Announces Debt Settlement FSD Pharma settles debt with shares issuance and grants RSUs to consultants. Company dedicated to biopharmaceutical innovation for neurodegenerative, metabolic, and alcohol misuse disorders Debt Settlement FSD Pharma Neurodegenerative Disorders RSUs Biopharmaceutical Innovation
Published on 09/19/2024 at 23:15, 2 hours 52 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 3 hours 7 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 23:00, 3 hours 7 minutes ago Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Published on 09/19/2024 at 21:09, 4 hours 58 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 7 hours 23 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 8 hours 4 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 8 hours 15 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 8 hours 15 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 8 hours 22 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 8 hours 22 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 8 hours 22 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)